EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II, open-label, single-arm, study investigates the clinical benefit of everolimus combined with endocrine therapy (ET) in hormone receptor-positive (HR+), metastatic breast cancer (MBC) patients who progressed on prior PI3K inhibitor therapy (+ ET). The trial aims to determine if sequential inhibition of the PI3K/AKT/mTORC1 pathway retains efficacy post-PI3K inhibitor resistance, hypothesizing that everolimus will demonstrate a response rate exceeding the historical 9.5% observed in the BOLERO2 trial.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi z przerzutami, który ma mutację PI3K
- •Wcześniejsze leczenie inhibitorem CDK 4/6 w połączeniu z hormonoterapią
- •Wcześniejsze leczenie inhibitorem PI3K w połączeniu z hormonoterapią
✗ Disqualifies
- •Kobiety, które nie otrzymały wcześniej leczenia inhibitorem PI3K
Simplified criteria — AI translation
Trial details
- Minimum age
- 21 Years
- Last updated (source)
- June 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Ichilov-Sourasky Medical Center
Tel Aviv, Israel
Trial contact
Breast Cancer coordinator Breast Cancer coordinator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.